Stock listing
NASDAQ:HRMY Harmony Biosciences Holdings, Inc. Stock
Home listing (NASDAQ) of Harmony Biosciences Holdings, Inc.
Follow Harmony Biosciences Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:HRMY
$32.59 USD -0.52 (-1.6%)
Close on Nov 20, 2026
- Day range
- $32.51 – $33.43 USDNov 20, 2026
- Volume
- 582,639 sharesNov 20, 2026
- Market cap
- $1.91B USDAt the close on Nov 20, 2026 · price × 58.72M shares outstanding
- 52-week range
- $25.90 – $43.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $38.51M USDMedian day 871,271 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:HRMY · Home | $32.59 USD | -0.52 (-1.6%) | 582,639 | $32.68 | $33.43 | $32.51 | $33.11 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HRMY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $32.59 | -0.52 | -1.6% | $32.68 | $33.43 | $32.51 | 582,639 | |
| $33.11 | +0.10 | +0.3% | $33.01 | $33.40 | $32.73 | 565,813 | |
| $33.01 | +0.05 | +0.2% | $32.96 | $33.13 | $32.46 | 607,331 | |
| $32.96 | -0.80 | -2.4% | $33.78 | $34.01 | $32.87 | 710,506 | |
| $33.76 | -0.04 | -0.1% | $33.80 | $34.32 | $33.01 | 844,890 | |
| $33.80 | -0.42 | -1.2% | $34.18 | $34.26 | $33.19 | 936,219 | |
| $34.22 | +0.67 | +2.0% | $33.35 | $34.38 | $33.26 | 971,350 | |
| $33.55 | -0.23 | -0.7% | $33.39 | $33.81 | $33.10 | 1,326,800 | |
| $33.78 | +0.67 | +2.0% | $33.25 | $33.83 | $32.68 | 792,900 | |
| $33.11 | +0.64 | +2.0% | $32.70 | $33.38 | $32.27 | 786,742 | |
| $32.47 | -1.945 | -5.7% | $35.68 | $35.68 | $32.31 | 1,477,499 | |
| $34.42 | -2.605 | -7.0% | $34.50 | $35.86 | $32.61 | 2,469,127 | |
| $37.02 | -0.89 | -2.3% | $37.97 | $38.74 | $36.38 | 1,445,070 | |
| $37.91 | -0.85 | -2.2% | $38.77 | $39.03 | $37.69 | 993,610 | |
| $38.76 | +0.17 | +0.4% | $38.58 | $39.10 | $38.39 | 871,271 | |
| $38.59 | +0.09 | +0.2% | $38.65 | $39.20 | $38.04 | 778,846 | |
| $38.50 | +0.55 | +1.4% | $37.72 | $38.53 | $37.28 | 1,002,679 | |
| $37.95 | +1.12 | +3.0% | $36.90 | $37.98 | $36.62 | 736,911 | |
| $36.83 | +0.70 | +1.9% | $36.28 | $37.19 | $36.13 | 850,295 | |
| $36.13 | +0.10 | +0.3% | $36.11 | $37.05 | $35.00 | 2,313,565 | |
| $36.03 | -2.28 | -6.0% | $38.50 | $39.64 | $34.11 | 2,905,502 | |
| $38.31 | -0.39 | -1.0% | $38.58 | $38.93 | $38.13 | 1,062,532 | |
| $38.70 | +1.16 | +3.1% | $37.99 | $39.23 | $37.49 | 798,585 | |
| $37.54 | -0.41 | -1.1% | $37.84 | $37.97 | $37.17 | 1,008,466 | |
| $37.95 | -0.32 | -0.8% | $38.47 | $39.00 | $37.85 | 892,300 | |
| $38.27 | +0.76 | +2.0% | $38.04 | $39.00 | $38.00 | 798,300 | |
| $37.51 | +0.48 | +1.3% | $37.16 | $38.31 | $36.92 | 972,200 | |
| $37.03 | -1.20 | -3.1% | $37.91 | $38.17 | $35.99 | 1,419,000 | |
| $38.23 | -2.05 | -5.1% | $38.34 | $39.89 | $37.01 | 1,148,400 | |
| $40.28 | +0.68 | +1.7% | $39.53 | $40.57 | $39.51 | 487,100 | |
| $39.60 | +0.26 | +0.7% | $39.14 | $39.89 | $38.68 | 865,000 | |
| $39.34 | -0.02 | -0.1% | $39.27 | $39.86 | $39.10 | 547,000 | |
| $39.36 | -0.56 | -1.4% | $40.09 | $40.35 | $38.91 | 507,300 | |
| $39.92 | +0.28 | +0.7% | $39.76 | $40.77 | $39.51 | 897,900 | |
| $39.64 | +0.07 | +0.2% | $39.78 | $40.62 | $39.25 | 916,700 | |
| $39.57 | +0.31 | +0.8% | $39.58 | $40.46 | $39.08 | 1,227,700 | |
| $39.26 | -0.03 | -0.1% | $39.30 | $39.56 | $38.72 | 667,500 | |
| $39.29 | -0.72 | -1.8% | $39.87 | $40.52 | $39.15 | 786,700 | |
| $40.01 | -1.25 | -3.0% | $41.29 | $41.54 | $39.54 | 874,400 | |
| $41.26 | +0.10 | +0.2% | $41.37 | $41.60 | $40.89 | 556,900 | |
| $41.16 | +0.68 | +1.7% | $40.63 | $41.79 | $40.00 | 906,400 | |
| $40.48 | -1.05 | -2.5% | $41.61 | $42.08 | $39.72 | 1,080,600 | |
| $41.53 | -0.57 | -1.4% | $42.10 | $42.37 | $41.36 | 577,900 | |
| $42.10 | +0.08 | +0.2% | $41.87 | $42.52 | $41.20 | 839,000 | |
| $42.02 | -0.72 | -1.7% | $42.57 | $43.27 | $41.90 | 3,820,500 | |
| $42.74 | +0.53 | +1.3% | $42.59 | $43.01 | $42.10 | 641,400 | |
| $42.21 | +0.04 | +0.1% | $42.28 | $43.05 | $42.06 | 1,599,200 | |
| $42.17 | +0.63 | +1.5% | $41.64 | $42.19 | $40.94 | 1,212,500 | |
| $41.54 | +0.02 | 0.0% | $41.93 | $42.25 | $41.48 | 1,044,200 | |
| $41.52 | +0.42 | +1.0% | $41.30 | $41.72 | $40.92 | 1,123,400 | |
| $41.10 | -0.52 | -1.2% | $41.26 | $41.72 | $40.93 | 736,800 | |
| $41.62 | -0.45 | -1.1% | $42.01 | $42.41 | $41.23 | 1,132,800 | |
| $42.07 | -0.18 | -0.4% | $42.20 | $43.25 | $41.56 | 1,778,100 | |
| $42.25 | +0.39 | +0.9% | $41.50 | $42.34 | $41.36 | 661,500 | |
| $41.86 | -1.00 | -2.3% | $42.93 | $43.49 | $41.40 | 1,100,600 | |
| $42.86 | +1.61 | +3.9% | $41.31 | $43.02 | $41.25 | 1,167,300 | |
| $41.25 | +1.87 | +4.7% | $39.38 | $41.49 | $39.38 | 894,500 | |
| $39.38 | +0.17 | +0.4% | $38.97 | $39.75 | $38.97 | 560,200 | |
| $39.21 | -0.66 | -1.7% | $39.69 | $39.69 | $39.13 | 590,200 | |
| $39.87 | +0.21 | +0.5% | $39.90 | $40.00 | $39.16 | 499,000 | |
| $39.66 | +0.71 | +1.8% | $39.74 | $40.50 | $38.87 | 744,700 | |
| $38.95 | +0.45 | +1.2% | $38.56 | $39.22 | $38.34 | 375,521 | |
| $38.50 | +0.35 | +0.9% | $38.13 | $38.93 | $37.48 | 486,067 | |
| $38.15 | +0.08 | +0.2% | $38.12 | $38.84 | $38.02 | 380,000 | |
| $38.07 | -1.86 | -4.7% | $39.61 | $40.02 | $37.93 | 696,100 |
- Ticker
- NASDAQ:HRMY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Harmony Biosciences to Participate in Upcoming Investor Conferences
Latest earnings call · Nov 4, 2026
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 22 slides
Latest news
Harmony Biosciences to Participate in Upcoming Investor Conferences
Nov 19, 2026
Closed $32.59 (-1.6%) on Nov 20, 2026
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
Nov 4, 2026
Closed $34.42 (-7.0%) on Nov 4, 2026
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Oct 20, 2026
Closed $38.70 (+3.1%) on Oct 20, 2026
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Oct 12, 2026
Closed $38.23 (-5.1%) on Oct 12, 2026
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Oct 1, 2026
Closed $39.57 (+0.8%) on Oct 1, 2026
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Sep 3, 2026
Closed $41.86 (-2.3%) on Sep 3, 2026
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Aug 27, 2026
Closed $39.87 (+0.5%) on Aug 27, 2026
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Aug 4, 2026
Closed $38.78 (+8.9%) on Aug 4, 2026
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Jul 21, 2026
Closed $36.84 (+10.0%) on Jul 21, 2026
Harmony Biosciences Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 175 in all · newest Nov 19, 2026 · oldest 2020
- Calls
- 24 calls with a replay · 24 with a transcript · latest Nov 4, 2026
- Decks
- 29 decks · latest Nov 4, 2026
Where Harmony Biosciences Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:HRMY · Home listing · This page | NASDAQ | United States | USD |
| BMV:HRMY | BMV | Mexico | MXN |
| BIVA:HRMY | BIVA | Mexico | MXN |
| Stuttgart:60H | Stuttgart | Germany | EUR |
| BOATS:HRMY | BOATS | United States | USD |
Valuation
P/E 10.7× against a median of 23.4×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.29B USD
- P/E
- 10.7×
- EV/sales
- 1.3×
- EV/EBITDA
- 5.4×
- Price/book
- 1.8×
- Gross margin
- 74.0%
- Operating margin
- 22.2%
- Net margin
- 18.1%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.57
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY | US$1.91B | US$1.29B | 10.7× | 1.3× | 5.4× | 1.8× | 18.1% | 0.1× | 0.57 |
| Henan Lingrui Pharmaceutial Co., Ltd. Class A · SSE:600285 | US$2.04B | US$1.89B | 16.4× | 3.2× | n/a | 3.9× | 20.9% | 0.0× | n/a |
| Novast Laboratories Ltd · SZSE:301569 | US$2.01B | US$1.80B | 43.0× | 11.9× | n/a | 5.9× | 30.8% | 0.0× | n/a |
| Aurinia Pharmaceuticals Inc · NASDAQ:AUPH | US$1.97B | US$1.92B | 6.3× | 6.0× | n/a | 3.0× | 97.7% | 0.0× | 0.64 |
| Alivus Life Sciences Ltd · NSE:ALIVUS | US$1.90B | US$1.80B | 26.3× | 6.2× | 18.1× | 4.9× | 24.9% | 0.0× | n/a |
| Pfizer Limited · NSE:PFIZER | US$1.90B | US$1.24B | 20.5× | 4.3× | 11.8× | 4.0× | 32.4% | 0.0× | n/a |
| Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A · SSE:603707 | US$1.90B | US$1.52B | 29.8× | 2.5× | n/a | 1.8× | 10.4% | 0.0× | n/a |
| Shenzhen Kangtai Biological Products Co. Ltd. Class A · SZSE:300601 | US$1.80B | US$1.74B | 103× | 4.7× | n/a | 1.2× | 4.8% | 0.2× | n/a |
| Shilpa Medicare Limited · NSE:SHILPAMED | US$1.79B | US$1.85B | 50.0× | 9.3× | 33.5× | 6.0× | 18.1% | 0.2× | n/a |
| Dermapharm Holding SE · XETR:DMP | US$1.78B | US$2.88B | 12.4× | 2.2× | 6.9× | 2.9× | 11.1% | 2.0× | n/a |
| Shenyang Xingqi Pharmaceutical Co., Ltd. Class A · SZSE:300573 | US$1.76B | US$1.69B | 14.6× | 4.0× | n/a | 5.2× | 28.6% | 0.0× | n/a |
| Median of the others | US$1.90B | US$1.80B | 23.4× | 4.5× | 14.9× | 4.0× | 22.9% | 0.0× | 0.64 |
Forecasts
6 strong buy · 2 buy · 3 hold · 1 sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 48.08 USD · Analysts' mean
- EPS, year to Dec 2026
- 4.76 · 2 analysts
- Revenue, year to Dec 2026
- 1.03B · 12 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Andreas Wicki | Chief Executive Officer |
| Ron Philip | President and Chief Executive Officer |
| Glenn Reicin | Chief Financial Officer |
| Peter Anastasiou | Chief Operating Officer |
| Christian Ulrich | Executive Vice President, General Counsel & Corporate Secretary |
| Adam Zaeske | Executive Vice President and Chief Commercial Officer |
| Cate McCanless | Senior Vice President and Chief Corporate Affairs Officer |
| David Unger | Senior Vice President, CMC and Technical Operations |
| Stephen Mollichella | Senior Vice President and Controller, Interim Principal Financial Officer |
| Andrew Serafin | Chief Strategy Officer |
| Audrey Murphy | Chief Human Resources Officer |
| Jeffrey S. Aronin | Harmony Founder and Non-Executive Chairman |
| Kumar Budur | Chief Medical and Scientific Officer |
| Tricia Glover | Chief Compliance Officer |
Board
| Director | Role |
|---|---|
| Jeffrey S. Aronin | Harmony Founder and Non-Executive Chairman |
Events
Calls
All 24 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | −7.0% |
| Q2 2026 | Aug 4, 2026 · Before open | +8.9% |
| Q1 2026 | May 7, 2026 · Before open | −4.2% |
| Q4 2025 | Feb 24, 2026 | +4.9% |
| Q3 2025 | Nov 4, 2025 · Before open | +4.7% |
| Q2 2025 | Aug 5, 2025 · Before open | −1.7% |
| Q1 2025 | Apr 28, 2025 · Before open | −0.8% |
| Q4 2024 | Feb 25, 2025 · Before open | +8.2% |
| Q3 2024 | Oct 29, 2024 · Before open | +16.1% |
| Q2 2024 | Aug 6, 2024 · Before open | +6.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 30, 2024 · Before open | +5.7% |
| Q4 2023 | Feb 22, 2024 · Before open | −4.7% |
| Q3 2023 | Oct 31, 2023 · Before open | +19.4% |
| Q2 2023 | Aug 1, 2023 · Before open | −3.9% |
| Q1 2023 | May 2, 2023 · Before open | +2.4% |
| Q4 2022 | Feb 21, 2023 · Before open | −11.1% |
| Q3 2022 | Nov 1, 2022 · Before open | +14.0% |
| Q2 2022 | Aug 2, 2022 · Before open | +12.6% |
| Q1 2022 | May 3, 2022 · Before open | −17.6% |
| Q4 2021 | Feb 28, 2022 · Before open | +5.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 22 slides | Nov 4, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 20 slides | Aug 4, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 26 slides | May 7, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 19 slides | May 7, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 18 slides | Feb 24, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 26 slides | Jan 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 17 slides | Nov 4, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 16 slides | Aug 5, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 16 slides | May 6, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 18 slides | Feb 25, 2025 |
All 29 decks
IPO
Priced at US$24.00 a share on Aug 18, 2020.
- Price
- US$24.00 a share
- Shares offered
- 5,348,837 shares of common stock
- Offering size
- US$128.4 million
- Underwriters' option
- Up to 802,325 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Piper Sandler · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2020 |
| Filed publicly | Jul 27, 2020 |
| Amended 3 times | Newest Aug 13, 2020 |
| Shares registered with an exchange | Aug 14, 2020 |
| Declared effective by the SEC | Aug 18, 2020 |
| Final prospectus, with the price | Aug 20, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 20, 2020 |
| EFFECT · Notice that a registration is effective | Aug 18, 2020 |
| S-1MEF · Registration of more shares for the same offering | Aug 18, 2020 |
| CERT · Exchange's certificate of listing | Aug 18, 2020 |
| CORRESP · Letter to the SEC | Aug 14, 2020 |
| CORRESP · Letter to the SEC | Aug 14, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 14, 2020 |
| S-1/A · Registration statement, amended | Aug 13, 2020 |
| S-1/A · Registration statement, amended | Aug 11, 2020 |
| S-1/A · Registration statement, amended | Aug 6, 2020 |
All 16 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 31, 2020 |
| S-1 · Registration statement | Jul 27, 2020 |
| DRS/A · Draft registration statement, amended | Jun 12, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jun 11, 2020 |
| UPLOAD · Letter from the SEC | Mar 12, 2020 |
| DRS · Draft registration statement | Feb 14, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 20, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 868.5M | 714.7M | 582.0M | 437.9M | 305.4M | 159.7M | 6.00M | 0 |
| Cost of revenue | 198.3M | 156.8M | 121.2M | 83.5M | 55.5M | 27.7M | 1.58M | 184.0K |
| Gross profit | 670.1M | 557.9M | 460.8M | 354.4M | 249.9M | 132.0M | 4.42M | -184.0K |
| Research and development | 189.6M | 145.8M | 76.1M | 70.9M | 30.4M | 19.4M | 69.6M | 12.4M |
| Selling, general and administrative | 152.5M | 110.4M | 95.3M | 84.0M | 63.9M | 39.7M | 36.4M | 12.2M |
| Operating income | 208.5M | 190.8M | 192.0M | 120.2M | 87.5M | 17.0M | -145.9M | -41.4M |
| Depreciation and amortization | 25.3M | 267.0K | 514.0K | 419.0K | 416.0K | 394.0K | 395.0K | 184.0K |
| EBITDA | 233.8M | 191.1M | 192.5M | 120.6M | 87.9M | 17.4M | -145.5M | -41.3M |
| Interest expense | 14.6M | 17.5M | 23.8M | 18.8M | 24.2M | 28.6M | 7.36M | 0 |
| Income before tax | 215.1M | 191.8M | 173.4M | 104.7M | 37.4M | -36.9M | -152.0M | -39.9M |
| Income tax | 56.4M | 46.3M | 44.5M | -76.8M | 2.83M | 14.9M | 6.07M | 1.54M |
| Net income | 158.7M | 145.5M | 128.9M | 181.5M | 34.6M | -36.9M | -152.0M | -39.9M |
| Earnings per share, basic | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -2.48 | -24.07 | -0.81 |
| Earnings per share, diluted | 2.71 | 2.51 | 2.13 | 2.97 | 0.58 | -2.48 | -24.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 752.5M | 453.0M | 311.7M | 243.8M | 234.3M | 228.6M | 24.5M | 83.5M |
| Short-term investments | 22.8M | 14.2M | 41.8M | 79.3M | 0 | |||
| Receivables | 96.8M | 83.0M | 74.1M | 54.7M | 34.8M | 22.2M | 4.25M | 0 |
| Inventory | 5.36M | 7.20M | 5.36M | 4.30M | 4.43M | 3.82M | 1.09M | 0 |
| Current assets | 907.0M | 579.3M | 451.1M | 400.3M | 284.4M | 262.9M | 31.5M | 86.7M |
| Property, plant and equipment | 1.26M | 371.0K | 573.0K | 820.0K | 938.0K | 1.33M | 1.58M | |
| Total assets | 1.27B | 999.2M | 811.4M | 673.9M | 433.4M | 427.1M | 106.7M | 89.3M |
| Accounts payable | 17.7M | 13.7M | 17.7M | 3.79M | 1.00M | 2.56M | 6.36M | 1.46M |
| Current liabilities | 252.1M | 175.1M | 163.8M | 78.9M | 53.8M | 134.5M | 19.9M | 7.23M |
| Long-term debt | 143.7M | 163.0M | 178.6M | 189.6M | 190.0M | 194.3M | 97.9M | |
| Total debt | 163.7M | 179.3M | 193.6M | 191.6M | 192.0M | 194.3M | 97.9M | 324.2M |
| Total liabilities | 401.4M | 340.0M | 344.5M | 271.0M | 246.9M | 329.9M | 118.3M | 7.75M |
| Shareholders' equity | 870.2M | 659.2M | 467.0M | 402.8M | 186.5M | 97.2M | -422.9M | 81.5M |
| Shares outstanding | 57.7M | 57.1M | 56.8M | 59.6M | 58.8M | 56.9M | 7.79M | 49.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 348.2M | 219.8M | 219.4M | 144.5M | 98.6M | -2.98M | -75.4M | -38.8M |
| Capital spending | -310.0K | -1.15M | -312.0K | -172.0K | -298.0K | -2.00K | -149.0K | -1.34M |
| Free cash flow | 347.9M | 218.7M | 219.1M | 144.3M | 98.3M | -2.99M | -75.6M | -40.1M |
| Cash from investing | -39.6M | -67.5M | -46.4M | -141.8M | -100.3M | -2.00M | -127.1M | -1.34M |
| Cash from financing | -9.05M | -11.0M | -105.6M | 6.84M | 7.42M | 209.2M | 143.8M | 21.6M |
| Dividends paid | -5.05M | -200.3M | -143.8M | |||||
| Share buybacks | 0 | 0 | -100.0M | 8.84M | 39.1M | -167.0K | -1.13M | -3.20M |
| Change in cash | 299.5M | 141.3M | 67.4M | 9.47M | 5.68M | 204.2M | -58.8M | -18.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 8-K/A · Current report, amended | Oct 30, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 16, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 18, 2026 | Insider trade | SEC |
| 8-K · Current report | May 14, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 14, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 6, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 3, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 3, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 8-K · Current report | Oct 23, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | May 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 8-K · Current report | May 15, 2025 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 7, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Apr 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 4, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 3, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Apr 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 28, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 24, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2025 | Offer document | SEC |
| S-3ASR · Registration statement | Feb 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 13, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 31, 2024 | Insider trade | SEC |
| 424B7 · Prospectus | Oct 31, 2024 | Offer document | SEC |
| 424B7 · Prospectus | Oct 29, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Oct 29, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 29, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 3, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Apr 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 11, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 11, 2024 | Material contract | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 11, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 8, 2024 | Other filings | SEC |
| 10-K/A · Annual report, amended | Feb 28, 2024 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Feb 22, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 22, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 22, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
This page holds 200 of 461 filings. Open Filings
Cap table
Built by 6ix from Harmony Biosciences Holdings, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 58,723,199
- Fully diluted
- 58,723,199
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 58,723,199 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 58,723,199 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gary Sender Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); iBio, Inc. (Director · Since at least Oct 14, 2020); Schrodinger, Inc. (Board Member · Since at least Feb 5, 2020); Nabriva Therapeutics AG (Chief Financial Officer · Dec 30, 2016 – Feb 28, 2021 · Past); Synergy Pharmaceuticals Inc (EVP and CFO · Nov 16, 2015 – Nov 16, 2015 · Past) | Director · Since at least Aug 18, 2020 |
| Geno Germano Other companies: Entera Bio Ltd. (Chairman of the Board · Since at least Feb 4, 2026); Precision BioSciences, Inc. (Director · Since at least Mar 10, 2020); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past) | Director · Since at least Apr 2, 2026 |
| Troy Ignelzi Other companies: Rapport Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 6, 2024); Contineum Therapeutics, Inc. (Chief Financial Officer, Rapport Therapeutics, Inc. · Since at least May 20, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); Karuna Therapeutics Inc (Chief Financial Officer · Jun 27, 2019 – Aug 22, 2023 · Past); Scpharmaceuticals Inc (Chief Financial Officer · Nov 16, 2017 – Jan 17, 2018 · Past) | Director · Since at least Apr 2, 2026 |
| Mark Graf Other companies: Marqeta, Inc. (Director · Since at least Jul 19, 2024); Signet Jewelers Limited (Director · Since at least Jul 1, 2017); Discover Financial Services (EVP & Chief Financial Officer · Apr 11, 2011 – Jul 25, 2019 · Past); BNC Bancorp (Director · Jun 15, 2010 – Sep 14, 2010 · Past) | Director · Since at least Nov 11, 2020 |
| Antonio J. Gracias Other companies: Space Exploration Technologies Corp (Board Member · Since at least Jun 11, 2026); SolarCity (Director · Dec 12, 2012 – Nov 21, 2016 · Past); Tesla, Inc. (Director · Jun 25, 2010 – Feb 8, 2021 · Past) | Director · Since at least Aug 18, 2020 |
| Jack Nielsen Other companies: Aligos Therapeutics, Inc. (Director · Jun 23, 2022 – Feb 27, 2024 · Past); ALX Oncology Holdings Inc. (Director · Jun 15, 2022 – Jun 20, 2023 · Past); Instil Bio, Inc. (Director · May 20, 2022 – Jun 14, 2023 · Past) | Director · Mar 30, 2022 – May 29, 2024 · Past |
| Sandip Kapadia Other companies: Windward Bio Group AG (Experienced Life Sciences Board Member and Chief Financial Officer · Since at least Nov 16, 2026); Passage Bio, Inc. (Chief Financial Officer of Harmony Biosciences Holdings, Inc. · Since at least Feb 27, 2020); Intercept Pharmaceuticals Inc (CFO and Treasurer · Jul 1, 2016 – Jan 22, 2021 · Past) | CHIEF FINANCIAL OFFICER · Since at least Mar 29, 2021 |
| Andreas Wicki Other companies: Viela Bio Inc (Director · Oct 2, 2019 – Mar 13, 2021 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Mar 12, 2021 · Past) | Chief Executive Officer · Since at least Aug 18, 2020 |
| Glenn Reicin Other companies: Sigilon Therapeutics Inc (CHIEF FINANCIAL OFFICER · Dec 3, 2020 – Feb 11, 2021 · Past); Jasper Therapeutics, Inc. (Director · Nov 19, 2019 – Nov 19, 2019 · Past) | Chief Financial Officer · Since at least Apr 14, 2026 |
| Susan L Drexler Other companies: Rein Therapeutics, Inc. (See Remarks · Jun 15, 2022 – Jun 15, 2022 · Past); Kiora Pharmaceuticals, Inc. (Interim CFO · Apr 21, 2022 – Apr 21, 2022 · Past) | Chief Financial Officer · Aug 18, 2020 – Aug 18, 2020 · Past |
All 29 people
| Person | Seat |
|---|---|
| Jeffrey M. Dayno Other companies: Egalet Corporation (Chief Medical Officer · Jul 31, 2014 – Jun 8, 2017 · Past) | PRESIDENT, CEO, Director · Since at least Aug 18, 2020 |
| Jeffrey S. Aronin Other companies: Discover Financial Services (Director · May 16, 2019 – May 11, 2023 · Past) | Harmony Founder and Non-Executive Chairman · Since at least Aug 18, 2020 |
| John C. Jacobs Other companies: Novavax, Inc. (President and Chief Executive Officer · Since at least Jan 23, 2023) | PRESIDENT, CEO, Director · Aug 18, 2020 – Aug 15, 2022 · Past |
| Linda Szyper Other companies: Neos Therapeutics Inc (Director · Mar 19, 2021 – Mar 19, 2021 · Past) | Director · Since at least Nov 18, 2021 |
| Ron M Philip Other companies: Avalo Therapeutics, Inc. (Director · Since at least Jun 23, 2026) | Director · Since at least Apr 2, 2025 |
| Ron Philip Other companies: Avalo Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026) | President and Chief Executive Officer · Since at least Apr 3, 2025 |
| Adam Zaeske | Executive Vice President and Chief Commercial Officer · Since at least Mar 24, 2025 |
| Andrew Serafin | CHIEF STRATEGY OFFICER · Since at least Dec 2, 2022 |
| Audrey Murphy | Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Cate McCanless | Senior Vice President and Chief Corporate Affairs Officer · Since at least Oct 20, 2026 |
| Christian Ulrich | Executive Vice President, General Counsel & Corporate Secretary · Since at least Nov 5, 2026 |
| David Unger | Senior Vice President, CMC and Technical Operations · Since at least Nov 5, 2026 |
| Eric L Motley | Director · Nov 11, 2020 – May 20, 2021 · Past |
| Jeffrey Dierks | CHIEF COMMERCIAL OFFICER · Aug 18, 2020 – Mar 3, 2025 · Past |
| Juan A Sabater | Director · Since at least Aug 18, 2020 |
| Kumar Budur | Chief Medical and Scientific Officer · Since at least May 1, 2023 |
| Peter Anastasiou | Chief Operating Officer · Since at least Nov 5, 2023 |
| Stephen Mollichella | Senior Vice President and Controller, Interim Principal Financial Officer · Since at least Jul 16, 2026 |
| Tricia Glover | Chief Compliance Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Harmony Biosciences Holdings, Inc.